https://www.selleckchem.com/pr....oducts/Phenformin-hy
The CD40-bispecific γδ T-cell engager demonstrated lysis of leukemic cells by autologous Vγ9Vδ2 T cells present in patient-derived samples. Taken together, our CD40 bispecific γδ T-cell engager increased the sensitivity of leukemic cells to apoptosis and induced a potent Vγ9Vδ2 T cell-dependent antileukemic response. It may, therefore, represent a potential candidate for the development of novel treatments for B-cell malignancies.Metabolism is reprogrammed in cancer to fulfill the demands of malignant cells for cancer i
Like
Comment
Share
